PDCD2L

Across TCGA pan-cancer cohorts, PDCD2L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDCD2L data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PDCD2L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDCD2L expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where PDCD2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.991	0.748	.002	19	view →
PDAC	OS	Quartile	III,IV	0.598	0.177	.012	5	view →
LSCC	OS	Median	All	0.793	1.000	.025	3	view →
HNSC	DFS	Quartile	All	0.914	1.000	.033	2	view →
UCEC	DFS	Tertile	All	0.922	1.000	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDCD2L–LUAD (DFS)

Open the LUAD breakdown →